Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genmab |
---|---|
Information provided by: | Genmab |
ClinicalTrials.gov Identifier: | NCT00093314 |
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.
Condition | Intervention | Phase |
---|---|---|
Chronic Lymphocytic Leukemia |
Drug: HuMax-CD20 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open-Labeled, International, Multicenter, Dose Escalating, Phase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | Hx-CD20-402 |
Study First Received: | October 6, 2004 |
Last Updated: | January 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00093314 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Chronic Lymphocytic Leukemia B-cell Lymphoma |
Leukemia, Lymphoid Immunoproliferative Disorders Lymphoma, B-Cell Leukemia Lymphatic Diseases Chronic Lymphocytic Leukemia Antibodies |
B-cell Lymphomas Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, B-Cell Lymphoproliferative Disorders Leukemia, B-cell, Chronic Lymphoma Immunoglobulins |
Lymphatic Diseases Leukemia Neoplasms Leukemia, Lymphoid Immunoproliferative Disorders |
Neoplasms by Histologic Type Immune System Diseases Leukemia, Lymphocytic, Chronic, B-Cell Lymphoproliferative Disorders Leukemia, B-Cell |